Gefitinib-induced pyogenic granuloma in a patient with lung cancer
Sir, Gefitinib, a tyrosine kinase inhibitor (TKI), is commonly used as first-line targeted therapy in adenocarcinoma of the lung with epidermal growth factor receptor (EGFR) exon 19 and 21 mutation. [1] Gefitinib binds to the adenosine triphosphate-binding site of the EGFR tyrosine kinase enzyme, th...
Saved in:
Published in | Lung India Vol. 37; no. 1; pp. 71 - 72 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
India
Wolters Kluwer India Pvt. Ltd
01.01.2020
Medknow Publications and Media Pvt. Ltd Medknow Publications & Media Pvt. Ltd Wolters Kluwer - Medknow Wolters Kluwer Medknow Publications |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Sir, Gefitinib, a tyrosine kinase inhibitor (TKI), is commonly used as first-line targeted therapy in adenocarcinoma of the lung with epidermal growth factor receptor (EGFR) exon 19 and 21 mutation. [1] Gefitinib binds to the adenosine triphosphate-binding site of the EGFR tyrosine kinase enzyme, thereby inhibiting the activation of antiapoptotic signal transduction cascade, and results in uncontrolled cell proliferation. [...]the use of gefitinib has been increased in India, and physicians used to encounter such side effect frequently in patients receiving gefitinib. |
---|---|
Bibliography: | SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1 |
ISSN: | 0970-2113 0974-598X |
DOI: | 10.4103/lungindia.lungindia_277_19 |